← Back to Search

Unknown

LY3437943 for Obesity

Phase 1
Waitlist Available
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up predose up to 96 hours postdose
Awards & highlights

Study Summary

This trial will investigate the effect of a subcutaneous injection of LY3437943 on blood levels of midazolam, warfarin, and caffeine when taken orally as a drug cocktail in obese people. The study will last up to 25 weeks for each participant.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~predose up to 96 hours postdose
This trial's timeline: 3 weeks for screening, Varies for treatment, and predose up to 96 hours postdose for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
PK: AUC[0-∞] of Caffeine
PK: AUC[0-∞] of Warfarin
PK: Cmax of Caffeine
+3 more

Side effects data

From 2022 Phase 2 trial • 281 Patients • NCT04867785
20%
Decreased appetite
20%
Nausea
15%
Diarrhoea
11%
Constipation
11%
Vomiting
11%
Upper respiratory tract infection
11%
Urinary tract infection
7%
Fatigue
7%
Dyspepsia
4%
Anaemia
4%
Covid-19
4%
Lipase increased
4%
Dizziness
4%
Weight decreased
2%
Cellulitis
2%
Diabetic ketoacidosis
2%
Abdominal pain
2%
Eructation
2%
Headache
100%
80%
60%
40%
20%
0%
Study treatment Arm
12 mg LY3437943 (2 mg)
8 mg LY3437943 (2 mg)
Placebo
1.5 Milligram (mg) Dulaglutide
0.5 mg LY3437943
4 mg LY3437943 (2 mg)
4 mg LY3437943 (4 mg)
8 mg LY3437943 (4 mg)

Trial Design

1Treatment groups
Experimental Treatment
Group I: LY3437943 + Drug CocktailExperimental Treatment4 Interventions
Midazolam in combination with warfarin and caffeine (drug cocktail) administered orally followed by LY3437943 administered subcutaneously (SC) in week 1. At weeks 8, 12, & 16, the LY3437943 will be administered SC on Day 1 followed by midazolam in combination with warfarin and caffeine (drug cocktail) administered orally on Day 2.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Midazolam
2018
Completed Phase 4
~1910
Warfarin
2017
Completed Phase 4
~248220
Caffeine
2014
Completed Phase 3
~2980
LY3437943
2022
Completed Phase 2
~950

Find a Location

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,616 Previous Clinical Trials
3,201,138 Total Patients Enrolled
53 Trials studying Obesity
40,796 Patients Enrolled for Obesity
Study DirectorEli Lilly and Company
1,345 Previous Clinical Trials
405,332 Total Patients Enrolled
36 Trials studying Obesity
20,515 Patients Enrolled for Obesity

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there currently any vacancies in this clinical trial?

"According to the information on clinicaltrials.gov, enrollment for this trial has already concluded. It was initially published on July 8th 2022 and last updated on November 9th 2022. Despite not being able to join this particular study, there are still 957 other trials actively seeking participants presently."

Answered by AI

Has LY3437943 been authorized by the FDA?

"The safety of LY3437943 has been assessed as a 1, since this is its initial clinical trial stage and there is limited evidence regarding efficacy and security."

Answered by AI

Who meets the criteria for eligibility in this research project?

"Those hoping to join this medical trial should be of legal age (18 and up) and have a diagnosis of obesity. Approximately 30 participants are needed to complete the study."

Answered by AI

Is this research endeavor accepting people aged 45 and above as participants?

"This study is only open to individuals aged 18-70, as 202 studies have been conducted specifically with participants under the age of majority and 596 trials were undertaken using patients over 65 years old."

Answered by AI

Who else is applying?

What state do they live in?
Florida
Texas
How old are they?
18 - 65
What site did they apply to?
Covance Clinical Research Unit
Covance Dallas
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
Recent research and studies
clinicaltrials.govStudy
A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants
2022. "A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05445232.
~12 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top